Scarlett et al. conducted proteomic profiling of sera from cases of cholangiocarcinoma using SELDI-TOF MS and found that a serum peptide corresponding to a 4463 m/z peak had superior discriminatory ability to CA19-9 and CEA, but did not identify the peak [16]. This evidence concerns the gene CEACAM5 and cholangiocarcinoma.